ClinicalTrials.gg
CompletedNCT05684289Updated Aug 24, 2023

A Study Investigating the Safety, Tolerability, Drug Levels and Drug Effect of BMS-986278 in Healthy Adult Participants (Part 1) and Japanese Participants (Part 2)

A Phase 1 interventional study of BMS-986278 and Sildenafil in Healthy Participants, sponsored by Bristol-Myers Squibb. Completed at 2 sites in United States. Open to participants aged 35 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-24.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2023, 3 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
61
Allocation
Randomized
Ages
35 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Idiopathic Pulmonary Fibrosis by Bristol-Myers Squibb — 2 open to participants now, 3 under way, 2 of them phase 3. Idiopathic Pulmonary Fibrosis · Bristol-Myers Squibb.

Enrollment
6th of 10
61 · median 100
Started
2023
with 2 others
Phase 1
4 of 11
none open now
Registered
7th of 11
by date

Among the 11 studies in Idiopathic Pulmonary Fibrosis by Bristol-Myers Squibb, this one is the 6th largest by enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2023, is one of 4 in phase 1, and was the 7th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

2 of the 11 studies in Idiopathic Pulmonary Fibrosis by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 35 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Idiopathic Pulmonary Fibrosis by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, drug levels and drug effect of BMS-986278 in healthy adult participants and Japanese participants.

03

Conditions studied

  • Healthy Participants

Keywords

  • BMS-986278
  • Idiopathic Pulmonary Fibrosis (IPF)
  • Sildenafil
04

Who can participate

Ages eligible
35 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants in the Japanese cohort (Part 2) must be first generation Japanese (born in Japan, not living outside of Japan > 10 years, both parents ethnically Japanese).
  • (BMI) of 18.0 kilogram (kg)/meter (m)\^2 through 32.0 kg/m\^2, inclusive. BMI = weight (kg)/(height [m])\^2.
  • Body weight ≥ 50 kg for males and ≥ 45 kg for females.

Exclusion criteria

Exclusion Criteria:

  • Any significant acute or chronic medical illness.
  • Any gastrointestinal (GI) disease or surgery (including cholecystectomy) or other procedures (for example, bariatric procedures) that could affect drug absorption, distribution, metabolism, and excretion.
  • Any major surgery within 4 weeks of first study intervention administration.

Other protocol-defined inclusion/exclusion criteria apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    Part 1: BMS-986278 + Sildenafil

    Drug: BMS-986278 · Drug: Sildenafil

  • Placebo comparator
    Part 1: Placebo + Sildenafil

    Drug: Sildenafil · Drug: Placebo

  • Experimental
    Part 2: BMS-986278

    Drug: BMS-986278

  • Placebo comparator
    Part 2: Placebo

    Drug: Placebo

Interventions

  • Specified dose on specified days

  • Specified dose on specified days

  • DrugPlacebo

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Mean placebo-corrected change from baseline in systolic blood pressure (SBP) (Part 1)

    Time frame: Up to 16 days

  2. Maximum observed plasma concentration (Cmax) (Part 2)

    Time frame: Up to 14 days

  3. Time of maximum observed plasma concentration (Tmax) (Part 2)

    Time frame: Up to 14 days

  4. Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUC(0-T)) (Part 2)

    Time frame: Up to 14 days

Secondary outcomes

  1. Cmax (Part 1 and 2)

    Time frame: Up to 16 days

  2. Tmax (Part 1)

    Time frame: Up to 16 days

  3. AUC(0-T) (Part 1)

    Time frame: Up to 16 days

  4. Number of participants with adverse events (AEs) (Part 1 and 2)

    Time frame: 30 days after last dose

  5. Number of participants with serious adverse events (SAEs) (Part 1 and 2)

    Time frame: 30 days after last dose

  6. Number of participants with clinical laboratory abnormalities (Part 1 and 2)

    Time frame: 30 days after last dose

  7. Number of participants with physical examination abnormalities (Part 1 and 2)

    Time frame: 30 days after last dose

  8. Number of participants with vital sign abnormalities (Part 1 and 2)

    Time frame: 30 days after last dose

  9. Number of participants with electrocardiogram (ECG) abnormalities (Part 1 and 2)

    Time frame: 30 days after last dose

  10. Mean placebo-corrected change in diastolic blood pressure (DBP) (Part 1)

    Time frame: 30 days after last dose

  11. Area under the concentration-time curve in 1 dosing interval (AUC [TAU]) (Part 2)

    Time frame: Up to 14 days

07

Study locations

2 sites
  • Altasciences Clinical Los Angeles, Inc
    Cypress, California 90630, United States
  • Syneos Health Clinical Research Services, Llc
    Miami, Florida 33136, United States
08

References and documents

Individual participant data

Plan to share: No — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myers Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosurecommitment.html

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in May 2023, 3 months.

Of 60 industry-sponsored phase 1 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 3 months is below that.

Counting every sponsor, half of 75 studies reached it within 12 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2022
First posted
Jan 13, 2023
StartActual
Jan 3, 2023
Primary completionActual
May 2, 2023
CompletionActual
May 2, 2023
Last update
Aug 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05684289
Responsible party
Sponsor
First posted
Jan 13, 2023
Start date
Jan 3, 2023
Primary completion
May 2, 2023
Completion
May 2, 2023
Last update
Aug 24, 2023

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Admilparant · Sildenafil

Start the discussion